Physician profile
Anna C Munoz
NPI 1730632084
$3,602.44
in general payments reported to CMS, 2019-2025
26 companies · $860 in 2025
The $860 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $845 · 2023: $1,055 · 2024: $842 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.58 | 2022-2024 | |
| Abbott Laboratories | $316.74 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $308.90 | 2022-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $248.00 | 2022-2025 | Lokelma |
| Gilead Sciences, INC. | $212.72 | 2024 | Epclusa |
| Inspire Medical Systems, INC. | $204.07 | 2023-2024 | Inspire |
| Dexcom, INC. | $174.32 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $154.34 | 2022 | |
| Glaxosmithkline, LLC. | $152.06 | 2023-2025 | Benlysta, Arexvy, Shingrix |
| Optinose US, INC. | $138.58 | 2022 | |
| Biomarin Pharmaceutical INC. | $133.94 | 2025 | Voxzogo 1.2mg |
| Nevro Corp. | $126.18 | 2023-2024 | Senza |
| Kyowa Kirin, INC. | $125.00 | 2025 | |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $111.58 | 2024 | Gvoke Hypopen |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $104.03 | 2025 | Omnipod |
| Sage Therapeutics, LLC | $100.00 | 2025 | |
| Horizon Therapeutics Plc | $91.73 | 2023 | Krystexxa |
| Amylyx Pharmaceuticals, INC. | $83.36 | 2023 | Relyvrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.07 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.80 | 2023 | |
| Janssen Pharmaceuticals, INC | $72.84 | 2023 | Xarelto |
| Novo Nordisk INC | $20.75 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.82 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.77 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.